Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.

Cancer cocktails pairing Moderna’s mRNA-4359 with Merck’s Keytruda and Marengo’s invikafusp alfa with Gilead Sciences’ ...

The Department of Health says it is "aware" of the jab and is "exploring" how it can be made available "as soon as possible".

Cancer cells release tiny biological packages called extracellular vesicles (EVs) that help tumors grow and spread. A team ...

University Hospitals (UH) has received $12.5 million in transformational support from Dee and Jimmy Haslam to fuel research and drug development for chronic lymphocytic leukemia (CLL) and other rare ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

Suneel Kamath, MD, knows too well the sense of helplessness that comes with living through what he calls “the doughnut hole.” ...

KRAS was long thought undruggable in cancer until scientists discovered a hidden binding pocket in mutant KRAS, leading to ...

The results, published May 5 in Nature Genetics, offer a new way to understand the molecular roots of cancer — an especially ...

Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Receipt of previous ...